OPR - Delayed Quote • USD SYRS Jul 2024 2.500 call (SYRS240719C00002500) Follow 4.3000 0.0000 (0.00%) At close: January 24 at 11:29 AM EST Comparisons Indicators Technicals Corporate Events Chart Types Aggregated Types Draw Table View List View Grid View Detach Attach No Tool Measure UNDO Redo All All Favorites Text Statistics Technicals Fibonacci Markings Lines Annotation Arrow Line Horizontal Vertical Rectangle Trend Line Measurement Line Average Line Callout Channel Check Continuous Crossline Elliott Wave Ellipse Doodle Fib Projection Fib Arc Fib Fan Fib Time Zone Focus Gann Fan Gartley Heart Pitchfork Quadrant Lines Ray Regression Line Fib Retracement Star Speed Resistance Arc Speed Resistance Line Time Cycle Tirone Levels Volume Profile Cross Magnet Clear All Drawings Restore Default Parameters Date Close Open High Low Volume O H L C Vol AAPL Loading Chart for SYRS240719C00002500 1D 5D 1M 3M 6M YTD 1Y 2Y 5Y All Date Range 1 min 1 min 2 mins 3 mins 5 mins 15 mins 30 mins 1 hour 4 hours Recent News: SYRS The Zacks Analyst Blog Highlights Bristol Myers, Moderna, 2seventy bio, Amylyx Pharmaceuticals and Syros Pharmaceuticals Syros (SYRS) Up on FDA Fast Track Tag for Tamibarotene in AML Syros Pharmaceuticals (SYRS) Soars 22.2%: Is Further Upside Left in the Stock? Syros Receives Fast Track Designation from the FDA for Tamibarotene for the Treatment of Newly Diagnosed Unfit AML with RARA gene overexpression Syros Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4) Syros Pharmaceuticals, Inc. (NASDAQ:SYRS) Q4 2023 Earnings Call Transcript Syros Pharmaceuticals Full Year 2023 Earnings: Misses Expectations Syros Reports Fourth Quarter and Full Year 2023 Financial Results and Provides a Corporate Update Syros Announces Completion of Enrollment of 190 Patients Necessary to Support Primary Endpoint Analysis in SELECT-MDS-1 Phase 3 Trial Syros to Report Fourth Quarter and Full Year 2023 Financial Results on Wednesday, March 27, 2024 Syros to Participate in TD Cowen 44th Annual Health Care Conference Investors in Syros Pharmaceuticals (NASDAQ:SYRS) have seen respectable returns of 99% over the past year
